Towards evidence based medicine for paediatricians: What are the options for treating latent TB infection in children?

Amanda Gwee, Benjamin Coghlan, Nigel Curtis

Research output: Contribution to journalLetterOther

13 Citations (Scopus)

Abstract

Children with LTBI have a significant risk of developing active TB without treatment, including those that have been BCG-immunised.1 Progression to active TB has been reported in up to 40 of infected infants.2 Recommendations for the treatment of LTBI in children vary: the Centers for Disease Control and Prevention recommend 9 months of isoniazid monotherapy3; the UK NICE guidelines suggest 6 months of isoniazid monotherapy or 3 months of combination therapy with rifampicin plus isoniazid4; and Australian guidelines suggest 6?12 months of isoniazid monotherapy. 5 Isoniazid preventive therapy (IPT) has been reported to have a protective efficacy of up to 90 in compliant patients.6 However, low treatment completion rates which have been reported as low as 65 , limit the effectiveness of IPT.7 Of the 12 studies that met our criteria, 10 compared isoniazid monotherapy with shorter courses of: (i) rifampicin plus isoniazid (RH); (ii) rifampicin plus pyrazinamide (RZ); and (iii) rifampicin monotherapy (R).
Original languageEnglish
Pages (from-to)468 - 473
Number of pages6
JournalArchives of Disease in Childhood
Volume98
Issue number6
DOIs
Publication statusPublished - 2013

Cite this

@article{791d3f7b3e704c9a8e0e31a517572440,
title = "Towards evidence based medicine for paediatricians: What are the options for treating latent TB infection in children?",
abstract = "Children with LTBI have a significant risk of developing active TB without treatment, including those that have been BCG-immunised.1 Progression to active TB has been reported in up to 40 of infected infants.2 Recommendations for the treatment of LTBI in children vary: the Centers for Disease Control and Prevention recommend 9 months of isoniazid monotherapy3; the UK NICE guidelines suggest 6 months of isoniazid monotherapy or 3 months of combination therapy with rifampicin plus isoniazid4; and Australian guidelines suggest 6?12 months of isoniazid monotherapy. 5 Isoniazid preventive therapy (IPT) has been reported to have a protective efficacy of up to 90 in compliant patients.6 However, low treatment completion rates which have been reported as low as 65 , limit the effectiveness of IPT.7 Of the 12 studies that met our criteria, 10 compared isoniazid monotherapy with shorter courses of: (i) rifampicin plus isoniazid (RH); (ii) rifampicin plus pyrazinamide (RZ); and (iii) rifampicin monotherapy (R).",
author = "Amanda Gwee and Benjamin Coghlan and Nigel Curtis",
year = "2013",
doi = "10.1136/archdischild-2013-303876",
language = "English",
volume = "98",
pages = "468 -- 473",
journal = "Archives of Disease in Childhood",
issn = "0003-9888",
publisher = "BMJ Publishing Group",
number = "6",

}

Towards evidence based medicine for paediatricians: What are the options for treating latent TB infection in children? / Gwee, Amanda; Coghlan, Benjamin; Curtis, Nigel.

In: Archives of Disease in Childhood, Vol. 98, No. 6, 2013, p. 468 - 473.

Research output: Contribution to journalLetterOther

TY - JOUR

T1 - Towards evidence based medicine for paediatricians: What are the options for treating latent TB infection in children?

AU - Gwee, Amanda

AU - Coghlan, Benjamin

AU - Curtis, Nigel

PY - 2013

Y1 - 2013

N2 - Children with LTBI have a significant risk of developing active TB without treatment, including those that have been BCG-immunised.1 Progression to active TB has been reported in up to 40 of infected infants.2 Recommendations for the treatment of LTBI in children vary: the Centers for Disease Control and Prevention recommend 9 months of isoniazid monotherapy3; the UK NICE guidelines suggest 6 months of isoniazid monotherapy or 3 months of combination therapy with rifampicin plus isoniazid4; and Australian guidelines suggest 6?12 months of isoniazid monotherapy. 5 Isoniazid preventive therapy (IPT) has been reported to have a protective efficacy of up to 90 in compliant patients.6 However, low treatment completion rates which have been reported as low as 65 , limit the effectiveness of IPT.7 Of the 12 studies that met our criteria, 10 compared isoniazid monotherapy with shorter courses of: (i) rifampicin plus isoniazid (RH); (ii) rifampicin plus pyrazinamide (RZ); and (iii) rifampicin monotherapy (R).

AB - Children with LTBI have a significant risk of developing active TB without treatment, including those that have been BCG-immunised.1 Progression to active TB has been reported in up to 40 of infected infants.2 Recommendations for the treatment of LTBI in children vary: the Centers for Disease Control and Prevention recommend 9 months of isoniazid monotherapy3; the UK NICE guidelines suggest 6 months of isoniazid monotherapy or 3 months of combination therapy with rifampicin plus isoniazid4; and Australian guidelines suggest 6?12 months of isoniazid monotherapy. 5 Isoniazid preventive therapy (IPT) has been reported to have a protective efficacy of up to 90 in compliant patients.6 However, low treatment completion rates which have been reported as low as 65 , limit the effectiveness of IPT.7 Of the 12 studies that met our criteria, 10 compared isoniazid monotherapy with shorter courses of: (i) rifampicin plus isoniazid (RH); (ii) rifampicin plus pyrazinamide (RZ); and (iii) rifampicin monotherapy (R).

UR - http://adc.bmj.com/content/98/6/468.1.full.pdf

U2 - 10.1136/archdischild-2013-303876

DO - 10.1136/archdischild-2013-303876

M3 - Letter

VL - 98

SP - 468

EP - 473

JO - Archives of Disease in Childhood

JF - Archives of Disease in Childhood

SN - 0003-9888

IS - 6

ER -